These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20014880)

  • 21. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.
    Boockvar JA; Tsiouris AJ; Hofstetter CP; Kovanlikaya I; Fralin S; Kesavabhotla K; Seedial SM; Pannullo SC; Schwartz TH; Stieg P; Zimmerman RD; Knopman J; Scheff RJ; Christos P; Vallabhajosula S; Riina HA
    J Neurosurg; 2011 Mar; 114(3):624-32. PubMed ID: 20964595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metrorrhagia after intravitreal injection of bevacizumab.
    Rodrigues EB; Shiroma H; Meyer CH; Maia M; Farah ME
    Acta Ophthalmol Scand; 2007 Dec; 85(8):915-6. PubMed ID: 17645422
    [No Abstract]   [Full Text] [Related]  

  • 23. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.
    Chamberlain MC
    Cancer; 2010 Sep; 116(17):3988-99. PubMed ID: 20564141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retinal circulatory disturbances following intracameral injection of bevacizumab for neovascular glaucoma.
    Yokoyama K; Choshi T; Kimoto K; Shinoda K; Nakatsuka K
    Acta Ophthalmol; 2008 Dec; 86(8):927-8. PubMed ID: 18494739
    [No Abstract]   [Full Text] [Related]  

  • 25. [MR imaging for accurate response monitoring in glioblastoma multiforme during bevacizumab therapy].
    Korn A; Braun C; Fenchel M; Ernemann U; Horger M
    Rofo; 2012 May; 184(5):397-401. PubMed ID: 22576602
    [No Abstract]   [Full Text] [Related]  

  • 26. Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?
    Rieger J; Bähr O; Ronellenfitsch MW; Steinbach J; Hattingen E
    J Clin Oncol; 2010 Sep; 28(27):e477; author reply e478. PubMed ID: 20585096
    [No Abstract]   [Full Text] [Related]  

  • 27. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure.
    Kernt M; Neubauer AS; Kampik A
    Acta Ophthalmol Scand; 2007 Feb; 85(1):119-20. PubMed ID: 17244226
    [No Abstract]   [Full Text] [Related]  

  • 28. Bevacizumab and other targeted agents in the upfront treatment of glioblastoma.
    Clarke JL
    Semin Radiat Oncol; 2014 Oct; 24(4):273-8. PubMed ID: 25219812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of evasion to antiangiogenic therapy in glioblastoma.
    Rose SD; Aghi MK
    Clin Neurosurg; 2010; 57():123-8. PubMed ID: 21280504
    [No Abstract]   [Full Text] [Related]  

  • 30. Fluorescence-guided operation in recurrent glioblastoma multiforme treated with bevacizumab-fluorescence of the noncontrast enhancing tumor tissue?
    Wachter D; Kallenberg K; Wrede A; Schulz-Schaeffer W; Behm T; Rohde V
    J Neurol Surg A Cent Eur Neurosurg; 2012 Nov; 73(6):401-6. PubMed ID: 22777926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Mrugala MM
    Neurology; 2009 Feb; 72(8):773; author reply 773-4. PubMed ID: 19248218
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
    Kumar V; Ghosh B; Raina UK; Goel N
    Acta Ophthalmol; 2010 Mar; 88(2):e3; author reply e4. PubMed ID: 19549100
    [No Abstract]   [Full Text] [Related]  

  • 33. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.
    Agarwal S; Sane R; Oberoi R; Ohlfest JR; Elmquist WF
    Expert Rev Mol Med; 2011 May; 13():e17. PubMed ID: 21676290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose antiangiogenic therapy for glioblastoma: less may be more?
    de Groot JF
    Clin Cancer Res; 2011 Oct; 17(19):6109-11. PubMed ID: 21852387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells.
    von Baumgarten L; Brucker D; Tirniceru A; Kienast Y; Grau S; Burgold S; Herms J; Winkler F
    Clin Cancer Res; 2011 Oct; 17(19):6192-205. PubMed ID: 21788357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intra-arterial bevacizumab with blood brain barrier disruption in a glioblastoma xenograft model.
    Burkhardt JK; Santillan A; Hofstetter CP; Christos P; Berry N; Shin BJ; Foley CP; Gürsel DB; Ballon DJ; Gobin YP; Boockvar JA
    J Exp Ther Oncol; 2012; 10(1):31-7. PubMed ID: 22946342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab.
    Peter S; Hausmann N; Schuster A; Boehm HF
    Clin Exp Ophthalmol; 2008; 36(1):94-6. PubMed ID: 18290962
    [No Abstract]   [Full Text] [Related]  

  • 38. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Chamberlain MC
    Neurology; 2009 Feb; 72(8):772-3; author reply 773-4. PubMed ID: 19237713
    [No Abstract]   [Full Text] [Related]  

  • 39. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delayed rectovaginal fistula: a potential complication of bevacizumab (avastin).
    Ley EJ; Vukasin P; Kaiser AM; Ault G; Beart RW
    Dis Colon Rectum; 2007 Jun; 50(6):930. PubMed ID: 17429706
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.